Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared a post on X about a paper by Pasi A. Jänne et al. published in JAMA Network:
“Growing NSCLC data offer lessons for bladder cancer as prolonged OS with EVP brings more brain mets into view. T-DXd shows meaningful CNS activity that matters across GU practice.
- Systemic ORR 47 to 50 percent with brain mets
- Intracranial ORR 50 percent at 5.4 mg/kg
- Median PFS 7.1 months with brain mets
- Safety manageable, favoring 5.4 mg/kg
Reinforces the importance of anticipating CNS disease as outcomes improve.”
Title: Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases, A Secondary Analysis of Randomized Clinical Trials
Authors: Pasi A. Jänne, David Planchard, Koichi Goto, Egbert F. Smit, Adrianus Johannes de Langen, Yasushi Goto, Kiichiro Ninomiya, Toshio Kubo, Maurice Pérol, Enriqueta Felip, Hidetoshi Hayashi, Kazuhiko Nakagawa, Junichi Shimizu, Misako Nagasaka, Kaline Pereira, Ayumi Taguchi, Ahmed Ali, Maha Karnoub, Rie Yonemochi, David Leung, Bob T. Li
Read The Full Article in JAMA Network.
More posts featuring Katy Beckermann.